clinical managment of hepatitis c in an environment with limited acces to treatment andrzej horban...
TRANSCRIPT
![Page 1: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/1.jpg)
Clinical managment of hepatitis C in an environment with limited
acces to treatment
Andrzej Horban
Hospital of Infectious Diseases
Warsaw, Poland
![Page 2: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/2.jpg)
What means ” limited access” ?
1. Epidemiological situation
2. Surveillance study
3. Health care financing
4. Inclusions and exclusions criteria
5. Schema of treatment
6. Monitoring principles
![Page 3: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/3.jpg)
Therapeutic programmes in limited resources countries
• Who should be treated ?
– Staging
– Grading
![Page 4: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/4.jpg)
HCV Epidemiology in Poland
2004 - 2157 2005 - 23422006 - 28902007 - 2693
Since 1990, when the anti-HCV tests were introduced
18 years x 2000 -2500 persons = 36 000 – 45 000 persons= appr. 0,1 % of population ?
![Page 5: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/5.jpg)
HCV Epidemiology in Poland
• Cities: 6.5 / 100 000( male -7.1, female 6,0)
• Countryside: 2.9 / 100 000 ( male -3.6, female 2.1)
• Male: 20-24 years – 10,8 /100 000
• Female: 60-64 years - 9,4/ 100 000
Czaszkowski M., Kuszewski K., Przegl Epid 2005; 59(2):303-8National Hygiene Institute Report 2006
![Page 6: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/6.jpg)
HCV in Poland: therapeutic programs
• Therapeutic programs supported by National Health Fund
• 2000 procedures carried out in 63 centres
• Number of treated is limited to 2500 per year(patients are on waiting list)
![Page 7: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/7.jpg)
Therapies in Poland
• Number of centres in Poland– 63
• Number of therapies per month in all the centres– 1569
• From 1 therapy (Łuków) to 250 (Warsaw Hospitalof Infectious Diseases)
![Page 8: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/8.jpg)
Therapeutic programme using pegylated interferon in the treatment of CHC
– reimbursed by the National Health Fund (NFZ) in Poland
• Pegylated interferon alpha in the treatmentof chronic hepatitis C
• 1. Pelylated interferon alpha 2a
• 2. Pegylated interferon alpha 2b
• 3. other interferons
![Page 9: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/9.jpg)
Inclusion criteria for CHC treatment programmes – in Poland
• presence of HCV RNA in the serum or hepatic tissue
• determination of the number of HCV RNA unitsin the tested material
• determination of viral genotype
• chronic hepatitis and compensated cirrhosis
![Page 10: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/10.jpg)
Inclusion criteria for CHC treatment programmes – in Poland
• inflammatory lesions and fibrosis in the histopathology of the liver (patients with genotype 2 or 3 and those with contraindications for biopsy do not require liver biopsy)
• patients with extrahepatic manifestations of HCV infection should be treated irrespective of disease severity in the histopathological score
• age - now no limitation
![Page 11: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/11.jpg)
Exclusion criteria for CHC treatment programmes
only medical contraindication
![Page 12: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/12.jpg)
HCV in Poland: therapeutic programmes
– pegylated interferon alpha
Pegylated interferon alpha may be used in patients above 18 years of age
• in monotherapy – in patients with contraindications to ribavirin
• in combination with ribavirin – in patients with chronic hepatitis C, with recurrent infection or after an unsuccesfull treatment with interferon alpha or interferon alpha with ribavirin
![Page 13: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/13.jpg)
Therapeutic programmes– pegylated interferon alpha
Treatment of chronic hepatitis C is dependenton the genotype, early viral response and extrahepatic manifestations of HCV infection:
patients with genotype 2 or 3: 24-weeks therapy
note: in patients with genotype 3, in which undetectable HCV RNA was not achieved after 24 weeks and with liver fibrosis (staging) > 2:therapy up to 48 weeks
![Page 14: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/14.jpg)
Therapeutic programmes– pegylated interferon alpha
patients with genotype 1 or 4:therapy depending on the early viral response and staging
- patients with liver fibrosis (staging) </= 2, decreasing viraemia greater than 2 log is not seen after 12 weeks of treatment – therapy should be discontinued
but
- in patients with liver fibrosis > 2 therapy should be continue up to 48 weeks irrespective of reduction in viraemia
![Page 15: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/15.jpg)
Therapeutic programmes– pegylated interferon alpha
patients with extrahepatic manifestations of HCV infection should be treated for 48 weeks
irrespective of genotype and reduction in viraemia after 12 weeks
![Page 16: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/16.jpg)
Therapeutic programmes– pegylated interferon alpha
2008:
• in patients infected with HCV of genotype 1 (Pegasys or Pegintron) or genotype 4 (Pegasys),with viraemia < 600 000 IU/ml at beginning of treatment and undetectable HCV RNA after 4 weeks (RVR)
it is recommended to cut the duration of therapy down to 24 weeks
![Page 17: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/17.jpg)
Therapeutic programmes in Poland– outcome monitoring
• Since last year, a based internet system was introduced to monitor proper programme conducting
• It covers patient’s data at the point of admittance to the programme (personal ID, weight, drug name, dose, biopsy results, genotype, viraemia level),RVR, EVR, ETR, SVR , reasons for interruption of treatment
![Page 18: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/18.jpg)
Bosnia&Herzegovina
• Population - 3 500 000
• HCV Prevalence - % (number) -1 ( 35 000)
• Number of diagnosed – 554
• Number of treated - 543
• % treated of diagnosed - 98
• treatment reimbursment - no
• Limitation - yearly budget for treatment given every year by government
![Page 19: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/19.jpg)
Bosnia&Herzegovina
• Inclusion criteria - full diagnostic: HCV RNA (+),biopsy, genotype
• Exclusion criteria – age( over65), drug addiction(drug addicts, or less than 1 year of abstinence)
• Hospitals/Ambulatories – beginnging in hospitals, continue in outpatients clinics
• Treatment rules Genotype 1,4 – 48 weeks
• Treatment rules Genotype 2,3 – 24 weeks
• Monitoring– 12,48,72 weeks
• Response Guided Therapy - only with permission
![Page 20: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/20.jpg)
Estonia
• Population – 1 300 000
• HCV Prevalence - % (number) - 1,5 ( 19 500)
• Number of diagnosed - NA
• Number of treated - NA
• % treated of diagnosed - NA
• Full treatment reimbursment - yes
• Limitation - no
![Page 21: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/21.jpg)
Estonia
• Inclusion criteria - full diagnostic: HCV RNA (+), biopsy, genotype
• Exclusion criteria –
• Hospitals/Ambulatories –
• Treatment rules Genotype 1,4 – 48 weeks
• Treatment rules Genotype 2,3 – 24 weeks
• Monitoring– 4,12,48,72 weeks
• Response Guided Therapy - Yes
![Page 22: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/22.jpg)
Hungary
• Population – 10 000 000
• HCV Prevalence - % /number– 0.70/ 70 000
• Number of diagnosed - 1000
• Number of treated - 1000
• % treated of diagnosed – 100
• Full treatment reimbursment - yes
• Limitation - no
![Page 23: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/23.jpg)
Hungary
• Inclusion criteria - full diagnosis: HCV RNA (+), biopsy, genotype
• Exclusion criteria – only medical contrindication
• Hospitals/Ambulatories – hepatology outpatients clinics
• Treatment rules Genotype 1,4 – 48 weeks
• Treatment rules Genotype 2,3 – 24 weeks
• Monitoring – 12,48,72 weeks
• Response Guided Therapy - Yes
![Page 24: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/24.jpg)
Czech Republic
• Population – 10 200 000
• HCV Prevalence % /number– 0.20/ 20 400
• Number of diagnosed - 2000
• Number of treated - 600
• % treated of diagnosed – 30
• Full treatment reimbursment - yes
• Limitation - no
![Page 25: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/25.jpg)
Czech Republic
• Inclusion criteria - full diagnostic: HCV RNA (+), biopsy, genotype
• Exclusion criteria – active drug addicts
• Hospitals/Ambulatories – ambulatories
• Treatment rules Genotype 1,4 – 48 weeks
• Treatment rules Genotype 2,3 – 24 weeks/ sometimes 48 weeks
• Monitoring – 12,48,72 weeks
• Response Guided Therapy – not yet
![Page 26: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/26.jpg)
Bulgaria
• Population – 7 700 000
• HCV Prevalence % /number – 1.38/ 106 260
• Number of diagnosed - 2072
• Number of treated - 300
• % treated of diagnosed – 14.48
• Full treatment reimbursment - yes
• Limitation - yes, only 300 yearly
![Page 27: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/27.jpg)
Bulgaria
• Inclusion criteria - full diagnosis: HCV RNA (+), biopsy, genotype, elevated Alat
• Exclusion criteria – NA
• Hospitals/Ambulatories – ambulatories
• Treatment rules Genotype 1,4 – 48 weeks
• Treatment rules Genotype 2,3 – 24 weeks/ sometimes 48 weeks
• Monitoring – 12,48,72 weeks
• Response Guided Therapy – not yet
![Page 28: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/28.jpg)
Slovenia
• Population – 2 000 000
• HCV Prevalence - % /number– 1.38/ 106 260
• Number of diagnosed – approximately 2000 since 1993, 115 in 2008
• Number of treated - 115
• % treated of diagnosed –
• Full treatment reimbursment - yes
• Limitation - no
![Page 29: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/29.jpg)
Slovenia
• Inclusion criteria - full diagnosis: HCV RNA (+), biopsy, genotype, elevated AlAT
• Exclusion criteria – NA
• Hospitals/Ambulatories – ambulatories
• Treatment rules Genotype 1,4 – 48 weeks
• Treatment rules Genotype 2,3 – 24 weeks
• Monitoring – 12,48,72 weeks
• Response Guided Therapy – not yet
![Page 30: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/30.jpg)
Romania
• Population – 19 600 00
• HCV Prevalence - % /number– 4.90/ 960 400
• Number of diagnosed – approximately 2100
• Number of treated - 420
• % treated of diagnosed – 20%
• Full treatment reimbursment – 100% Pegasys, 25% Copegus
• Limitation - no
![Page 31: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/31.jpg)
Romania
• Inclusion criteria - full diagnosis: HCV RNA (+),age < 65, biopsy score >= 1, genotype, normal or elevated AlAT, naive or relapser ( Not NR)
• Exclusion criteria – age >65, liver biopsy <1
• Hospitals/Ambulatories – ambulatories
• Treatment rules Genotype 1,4 – 48 weeks
• Treatment rules Genotype 2,3 – 24 weeks
• Monitoring – 12,48,72 weeks
• Response Guided Therapy – not yet
![Page 32: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/32.jpg)
Macedonia
• Population – 2 000 000
• HCV Prevalence - % /number – 1,20/ 24 000
• Number of diagnosed - 1326
• Number of treated - 360
• % treated of diagnosed – 27,15
• Full treatment reimbursment – yes for limited group of patients
• Limitation - yes - hospital budget
![Page 33: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/33.jpg)
Macedonia
• Inclusion criteria - elevated ALT , biopsy result - hepatic damage
• Exclusion criteria – drug users with less than 6 months abstinence
• Hospitals/Ambulatories – hospitals
• Treatment rules Genotype 1,4 – 48 weeks
• Treatment rules Genotype 2,3 – 24 weeks/
• Monitoring – 12,48,72 weeks
• Response Guided Therapy – not yet
![Page 34: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/34.jpg)
Russia
• Population – 142 200 000
• HCV Prevalence - % /number– 1,30/ 1 848 600
• Number of diagnosed – 77 000
• Number of treated - 20 000
• % treated of diagnosed – 25,97
• Full treatment reimbursment – no
• Limitation - only some group of patience (cirrhosis, diabetes, haemophilia).Regional AIDS centres receive Pegays for treatment HIV-HCV coinfected pts in the frame of National priority project „Health”
![Page 35: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/35.jpg)
Russia
• Inclusion criteria
• Exclusion criteria
• Hospitals/Ambulatories – ambulatories
• Treatment rules Genotype 1,4 – 48 weeks
• Treatment rules Genotype 2,3 – 24 weeks/
• Monitoring – 4,12,48,72 weeks
• Response Guided Therapy – yes
![Page 36: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/36.jpg)
Croatia
• Population – 4 400 000
• HCV Prevalence - % /number– 1,4/ 61 600
• Number of diagnosed – 700
• Number of treated - 320
• % treated of diagnosed – 45,71
• Full treatment reimbursment – yes
• Limitation - hospitals
![Page 37: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/37.jpg)
Croatia
• Inclusion criteria - HCV – RNA positive, age<65, naiveor relapser (not NR), elevated ALT(>2x), Normal ALT activity (F2 and more) normal or high, liver biopsy score >= F1
• Exclusion criteria –
• Hospitals/Ambulatories – hospitals
• Treatment rules Genotype 1,4 – 48 weeks
• Treatment rules Genotype 2,3 – 24 weeks/
• Monitoring– standard 12,48,72 week, week 4 only in pts with genotype 1 with low wiremia
• Response Guided Therapy – yes
![Page 38: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/38.jpg)
Therapeutic programmes in limited resources countries
• Lack of surveillance study
• Gap between estimated seroprevalence and reality
• Access to treatment is limited
![Page 39: Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland](https://reader030.vdocuments.site/reader030/viewer/2022032703/56649d0a5503460f949dd049/html5/thumbnails/39.jpg)
Therapeutic programmes in limited resources countries
• Who should be treated ?
– Staging ?
– Grading ?